This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Jongsma, M. M. E. et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial. Gut https://doi.org/10.1136/gutjnl-2020-322339 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hindson, J. First-line infliximab for children with Crohn’s disease. Nat Rev Gastroenterol Hepatol 18, 150 (2021). https://doi.org/10.1038/s41575-021-00429-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-021-00429-1